scholarly journals Significance of transforming growth factor ?1 as a new tumor marker for colorectal cancer

2002 ◽  
Vol 97 (4) ◽  
pp. 508-511 ◽  
Author(s):  
Shin Narai ◽  
Masahiko Watanabe ◽  
Hirotoshi Hasegawa ◽  
Hideki Nishibori ◽  
Takashi Endo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Tumor Marker ◽  
Transforming Growth Factor

Plasma transforming growth factor-β1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker

Lung Cancer ◽  
1996 ◽  
Vol 16 (1) ◽  
pp. 47-59 ◽  
Author(s):  
Feng-Ming Kong ◽  
Mary Kay Washington ◽  
Randy L. Jirtle ◽  
Mitchell S. Anscher
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Tumor Marker ◽  
Transforming Growth Factor ◽  
Disease Status ◽  
Transforming Growth Factor Β1

scholarly journals miR-135b Promotes Cancer Progression by Targeting Transforming Growth Factor Beta Receptor II (TGFBR2) in Colorectal Cancer

PLoS ONE ◽  
2015 ◽  
Vol 10 (6) ◽  
pp. e0130194 ◽  
Author(s):  
Jialu Li ◽  
Hongwei Liang ◽  
Ming Bai ◽  
Tao Ning ◽  
Cheng Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Cancer Progression ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Beta Receptor ◽  
Growth Factor Beta

scholarly journals Human Colorectal Cancer from the Perspective of Mouse Models

Genes ◽  
2019 ◽  
Vol 10 (10) ◽  
pp. 788 ◽  
Author(s):  
Monika Stastna ◽  
Lucie Janeckova ◽  
Dusan Hrckulak ◽  
Vitezslav Kriz ◽  
Vladimir Korinek
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Mouse Models ◽  
Intracellular Signaling ◽  
Transforming Growth Factor ◽  
Molecular Subtype ◽  
Transforming Growth Factor Β ◽  
Dna Mismatch ◽  
Individual Mouse ◽  
Consensus Molecular Subtype

Colorectal cancer (CRC) is a heterogeneous disease that includes both hereditary and sporadic types of tumors. Tumor initiation and growth is driven by mutational or epigenetic changes that alter the function or expression of multiple genes. The genes predominantly encode components of various intracellular signaling cascades. In this review, we present mouse intestinal cancer models that include alterations in the Wnt, Hippo, p53, epidermal growth factor (EGF), and transforming growth factor β (TGFβ) pathways; models of impaired DNA mismatch repair and chemically induced tumorigenesis are included. Based on their molecular biology characteristics and mutational and epigenetic status, human colorectal carcinomas were divided into four so-called consensus molecular subtype (CMS) groups. It was shown subsequently that the CMS classification system could be applied to various cell lines derived from intestinal tumors and tumor-derived organoids. Although the CMS system facilitates characterization of human CRC, individual mouse models were not assigned to some of the CMS groups. Thus, we also indicate the possible assignment of described animal models to the CMS group. This might be helpful for selection of a suitable mouse strain to study a particular type of CRC.

scholarly journals Hyaluronic acid synthase 2 promotes malignant phenotypes of colorectal cancer cells through transforming growth factor beta signaling

2019 ◽  
Vol 110 (7) ◽  
pp. 2226-2236 ◽  
Author(s):  
Young‐Heon Kim ◽  
Seung Bum Lee ◽  
Sehwan Shim ◽  
Areumnuri Kim ◽  
Ji‐Hye Park ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hyaluronic Acid ◽  
Growth Factor ◽  
Cancer Cells ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Hyaluronic Acid Synthase ◽  
Colorectal Cancer Cells ◽  
Growth Factor Beta

scholarly journals Comprehensive assessment of variation at the transforming growth factor β type 1 receptor locus and colorectal cancer predisposition

2010 ◽  
Vol 107 (17) ◽  
pp. 7858-7862 ◽  
Author(s):  
Luis G. Carvajal-Carmona ◽  
Mike Churchman ◽  
Carolina Bonilla ◽  
Axel Walther ◽  
Jeremie H. Lefèvre ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Comprehensive Assessment ◽  
Cancer Predisposition ◽  
Receptor Locus

Do insulin-like growth factor associated proteins qualify as a tumor marker?

2012 ◽  
Vol 30 (30_suppl) ◽  
pp. 18-18
Author(s):  
Christiane Matuschek ◽  
Matthias Peiper ◽  
Wilfried Budach ◽  
Peter Arne Gerber ◽  
Hans Bojar ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Tumor Marker ◽  
Head And Neck ◽  
Sensitivity And Specificity ◽  
Metastatic Disease ◽  
Serum Levels ◽  
Insulin Like Growth Factor ◽  
Neck Tumors ◽  
Igf System

18 Background: Insulin-like growth factor (IGF)-1, -2 and insulin-like growth factor binding proteins (IGFBP) are involved in the proliferation and differentiation of cells. It has never been evaluated if the IGF-system can serve as a tumor marker in neoplasms. Methods: In our prospective study, 163 patients with colorectal cancer (22), prostate cancer (21), glioblastoma (12), head and neck tumors (17), lymphomas (20), lung cancer (34), and other entities (37) were analysed for their IGF and IGFBP serum levels at the beginning and the end of radiotherapy and compared with 13 healthy people. Subgroups of patients with local tumor disease versus metastatic disease, primary and recurrent therapy and curative versus palliative therapy were compared. Results: The serum levels of IGF-2 were significantly elevated in patients with prostate and colorectal cancer. However, sensitivity and specificity were only 70%. IGFBP-2 serum levels were elevated in patients with head and neck tumors. Again, sensitivity and specificity were only 73%. A difference between local disease and metastatic disease could not be found. A difference between IGF serum levels before and after radiotherapy could not be detected. Conclusions: The IGF-system cannot serve as a new tumor marker. The detected differences are very small and sensitivity and specificity are too low. IGF measurement is not useful for the evaluation of the success of radiotherapy in malignancies.

Sign in / Sign up

Export Citation Format

Share Document